A clinical trial to study the effects of platelet rich plasma in patients of melasma
Not Applicable
- Conditions
- Health Condition 1: L811- ChloasmaHealth Condition 2: L814- Other melanin hyperpigmentation
- Registration Number
- CTRI/2020/07/026311
- Lead Sponsor
- All India Institute of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients with facial melasma with bilateral involvement.
2.Age >= 18 yrs
Exclusion Criteria
1.Pregnancy and Lactation
2.Bleeding tendencies
3.On treatment with any topical or oral treatment of melsma at the time of study or in last two weeks(can be considered after wash-off of 2 weeks)
4.On treatment with laser/light ( can be considered after 4 weeks since last sitting)
5.Obvious infection of skin site
6.Hormone contraception or hormone replacement therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the additional benefit of Platelet Rich Plasma over and above standard hydroquinone cream on melasma reduction. <br/ ><br>To assess whether the recurrence free period is prolonged after application of platelet rich plasma therapy. <br/ ><br>To assess the side-effects occurring after the intervention.Timepoint: 4 weeks, 8 weeks, 12 weeks, 16 weeks
- Secondary Outcome Measures
Name Time Method To look at quality of life of patients suffering from melasma and how treatment influences quality of lifeTimepoint: 16 weeks